We’ve conducted more than 60 respiratory disease trials with nearly half of our experience in the two primary areas of threat: Asthma and COPD.
Respiratory drug development is no easy task, but our team of board-certified pulmonologists and recognized experts in pulmonary function testing is up for the challenge. We’ve established committee memberships and fellowships with several major professional societies, including the American Thoracic Society, European Respiratory Society, American College of Chest Physicians, and American Association for Respiratory Care, as well as relationships with other investigators and leaders in respiratory clinical research.
We specialize in the standardization of key respiratory assessments, and our expertise covers a wide range of indications, such as:
- Allergic Rhinitis
- Chronic Obstructive Pulmonary Disease (COPD)
- Cystic Fibrosis
- Pulmonary Fibrosis
In addition to managing more than 64 clinical development programs, we’ve also provided non-clinical services for more than 30 projects, and we’ve helped sponsors in the market approvals of three major respiratory drugs.
Leading the way in allergy drug research.
When it comes to allergy drug research, we are leading the conversation. More than 60 of our monitors and clinical team managers have experience with allergic rhinitis studies, and we’ve been involved in research on the majority of approved allergy medications currently on the US market.
A core aspect of the drug development landscape has been and always will be an intimate expertise in therapeutic areas. Our experts will partner with…
Collaboration Advances Small Pharma Company’s Pediatric Development Plan to First-in-Pediatrics RSV Study
A Phase II, randomized, double-blind, placebo-controlled, 2-part study to evaluate the safety, tolerability, pharmacokinetics, clinical response, and…